Real-world durability of effectiveness through 24 months of anti-interleukin (IL)-17A biologics and other approved biologics in treating patients with moderate-to-severe psoriasis in PSoHO


Por: Tjioe, M, Costanzo, A, Carrascosa, JM, Bovenschen, HJ, Maul, JT, de Hoog, N, Martimianaki, G, Lampropoulou, A, McKenzie, R, Pinter, A and Daniel, B

Publicada: 1 jun 2025
Resumen:


Filiaciones:
Tjioe, M:
 Bravis Hosp, DermaTeam Res, Roosendaal, Netherlands

Costanzo, A:
 Humanitas Univ, Milan, Italy

:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Barcelona, Spain

Bovenschen, HJ:
 Maxima Med Ctr Veldhoven, Veldhoven, Netherlands

Maul, JT:
 Univ Hosp Zurich, Zurich, Switzerland

de Hoog, N:
 Eli Lilly & Co, Indianapolis, IN USA

Martimianaki, G:
 Eli Lilly & Co, Indianapolis, IN USA

Lampropoulou, A:
 Eli Lilly & Co, Indianapolis, IN USA

McKenzie, R:
 Eli Lilly & Co, Indianapolis, IN USA

Pinter, A:
 Univ Zurich, Zurich, Switzerland

 Univ Hosp Frankfurt, Frankfurt, Germany

Daniel, B:
 St Vincents Hosp Melbourne, Melbourne, Australia
ISSN: 00048380





Australasian Journal of Dermatology
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Meeting Abstract
Volumen: 66 Número:
Páginas:
WOS Id: 001506991900177

MÉTRICAS